|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
European Patient Summary
|
|
|
|||||||||||||||||||
Problem list
| Condition | Onset Date / Period | Status |
|---|---|---|
| Type 2 diabetes mellitus | 20-Dec-2024 | active |
| Metabolic syndrome X | 07-Jul-2000 | active |
| Anemia | 09-Jun-1995 | active |
| Essential hypertension | 28-May-1993 | active |
| Viral sinusitis | 25-Mar-2020 - 08-Apr-2020 | inactive |
| Acute viral pharyngitis | 06-Jan-2020 - 18-Jan-2020 | inactive |
Medication list
| Medication | Since | Form | Dosage | Reason |
|---|---|---|---|---|
| Amlodipine (as amlodipine besylate) 2.5 mg oral tablet | 2024-12-20 | - | 1 tablet (2.5 mg) by mouth once daily | Essential hypertension (disorder) |
| Hydrochlorothiazide 25 mg oral tablet | 2024-12-20 | - | 1 tablet (25 mg) by mouth once daily | Essential hypertension (disorder) |
| Lisinopril 10 mg oral tablet | 2024-12-20 | - | 1 tablet (10 mg) by mouth once daily | Essential hypertension (disorder) |
| Acetaminophen 300 mg and codeine phosphate 15 mg oral tablet | 2024-12-20 | - | 1 tablet (300 mg/15 mg) every 4 to 6 hours as needed | - |
Immunizations list
| Vaccine | Date |
|---|---|
| Influenza virus antigen only vaccine product | 20-Dec-2024 |
| Clostridium tetani toxoid antigen adsorbed only vaccine product | 09-Dec-2022 |
| Live attenuated Human alphaherpesvirus 3 only vaccine product | 09-Dec-2022 |
| SARS-CoV-2 mRNA vaccine | 03-Sep-2021 |
Procedure History list
| No known procedures |
Allergies and Intolerances
| No known allergies or intolerances |
Care Plan
| Active Planned Care / Goals | Start Date | Reason |
|---|---|---|
| Therapy | 17-Mar-2014 | - |
| Lifestyle education regarding hypertension | 28-May-1993 | Essential hypertension (disorder) |
|
||
| Diabetes self management plan | 10-Apr-1992 | Prediabetes (finding) |
|
Vital Signs
| Vital Signs | 2024-12-20 | 2023-12-15 |
|---|---|---|
| Body Height | 186 cm | 186 cm |
| Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 {score} | 1 {score} |
| Body Weight | 94.5 kg | 94.5 kg |
| Body mass index (BMI) [Ratio] | 27.3 kg/m2 | 27.3 kg/m2 |
| Heart rate | 83 /min | 88 /min |
| Respiratory rate | 16 /min | 15 /min |
| Blood pressure panel with all children optional | 72 mm[Hg] | 71 mm[Hg] |
Relevant diagnostic tests/laboratory data
| Recent Lab Observations | 20-DEC-2024 | Reference Range | Unit |
|---|---|---|---|
| Hemoglobin A1c/Hemoglobin.total in Blood | 6.8 H | 4.8 - 5.9 | % |
| Glucose [Mass/volume] in Blood | 97.2 | 70 - 100 | mg/dL |
| Urea nitrogen [Mass/volume] in Blood | 9.2 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Blood | 1.5 H | 0.6 - 1.2 | mg/dL |
| Calcium [Mass/volume] in Blood | 9.7 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Blood | 141.1 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Blood | 5.1 H | 3.5 - 5.0 | mmol/L |
| Chloride [Moles/volume] in Blood | 102.9 | 98 - 107 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Blood | 20.9 L | 22 - 29 | mmol/L |
| Cholesterol [Mass/volume] in Serum or Plasma | 189.8 | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 105.1 | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 122.2 H | 0 - 100 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46.6 | 40 - 60 | mg/dL |
| Microalbumin/Creatinine [Mass Ratio] in Urine | 7.3 | 0 - 30 | mg/g |
Device Use
| Device | Date (since) |
|---|---|
| Blood glucose meter (physical object) | 10-Apr-1992 |